Global Myelodysplastic Syndrome (MDS) Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Myelodysplastic Syndrome (MDS) Treatment Market Research Report 2024
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
According to Mr Accuracy reports new survey, global Myelodysplastic Syndrome (MDS) Treatment market is projected to reach US$ 6102.7 million in 2029, increasing from US$ 3270 million in 2022, with the CAGR of 9.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Myelodysplastic Syndrome (MDS) Treatment market research.
The global market for myelodysplastic syndrome (MDS) treatment is expected to grow significantly over the coming years, owing to rising pipeline products and product approvals, as well as increased R&D investments in the development of novel drugs for MDS. For instance, Inqovi (decitabine and cedazuridine) tablets were approved by the United States Food and Drug Administration in July 2020 for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This is a significant advancement in treatment options for patients with MDS, a type of blood cancer which previously required intravenous therapy at a healthcare facility. Thus, the aforementioned factors are anticipated to contribute to the growth of the myelodysplastic syndrome (MDS) treatment market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Myelodysplastic Syndrome (MDS) Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.
Takeda Pharmaceutical Company Limited
Bristol-Myers Squibb
LUPIN
Pfizer Inc
Amgen Inc
Onconova Therapeutics
Astex Pharmaceutical
Helsinn Healthcare SA
Abbott
Boehringer Ingelheim International GmbH,
Johnson & Johnson Private Limited.
MEI Pharma Inc.
Aprea Therapeutics
Reddy's Laboratories Ltd.
AbbVie Inc.
Syros Pharmaceuticals
Acceleron Pharma, Inc.
Segment by Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Refractory Cytopenia with Unilineage Dysplasia
Refractory Anemia with Ringed Sideroblasts
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Myelodysplastic Syndrome (MDS) Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Myelodysplastic Syndrome (MDS) Treatment market is projected to reach US$ 6102.7 million in 2029, increasing from US$ 3270 million in 2022, with the CAGR of 9.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Myelodysplastic Syndrome (MDS) Treatment market research.
The global market for myelodysplastic syndrome (MDS) treatment is expected to grow significantly over the coming years, owing to rising pipeline products and product approvals, as well as increased R&D investments in the development of novel drugs for MDS. For instance, Inqovi (decitabine and cedazuridine) tablets were approved by the United States Food and Drug Administration in July 2020 for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This is a significant advancement in treatment options for patients with MDS, a type of blood cancer which previously required intravenous therapy at a healthcare facility. Thus, the aforementioned factors are anticipated to contribute to the growth of the myelodysplastic syndrome (MDS) treatment market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Myelodysplastic Syndrome (MDS) Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.
Takeda Pharmaceutical Company Limited
Bristol-Myers Squibb
LUPIN
Pfizer Inc
Amgen Inc
Onconova Therapeutics
Astex Pharmaceutical
Helsinn Healthcare SA
Abbott
Boehringer Ingelheim International GmbH,
Johnson & Johnson Private Limited.
MEI Pharma Inc.
Aprea Therapeutics
Reddy's Laboratories Ltd.
AbbVie Inc.
Syros Pharmaceuticals
Acceleron Pharma, Inc.
Segment by Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Segment by Application
Refractory Cytopenia with Unilineage Dysplasia
Refractory Anemia with Ringed Sideroblasts
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Myelodysplastic Syndrome (MDS) Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source